Macrophage migration inhibitory factor: Association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus

Human Immunology

Volumn 75, Issue 5, 2014, Pages 433-439

  De la Cruz Mosso, U ^a   Bucala, R ^b   Palafox Sanchez C A ^a   Parra Rojas, I ^c   Padilla Gutierrez J R ^a   Pereira Suarez A L ^a   Rangel Villalobos, H ^a   Vazquez Villamar M ^a   Angel Chavez L I ^a   Munoz Valle J F ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; AGED; ALLELE; BLOOD; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MEXICO; MIDDLE AGED; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MEXICO; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84896546417     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.02.014     Document Type: Article

References (48)

1. Manson J.J., Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis 2006, 1:6.
2. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121.
3. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
4. Pons-Estel G.J., Alarcón G.S., Scofield L., Reinlib L., Cooper G.S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010, 39:257-268.
5. Crispín J.C., Liossis S.-N.C., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.-T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
6. Moser K.L., Kelly J.A., Lessard C.J., Harley J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373-379.
7. Krishnamurthy S., Mahadevan S. Systemic lupus erythematosus: recent concepts in genomics, pathogenetic mechanisms, and therapies. ISRN Immunol 2011, 2011:1-7.
8. Yap D.Y.H., Lai K.N. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010, 2010:365083.
9. Zhu L.-J., Yang X., Yu X.-Q. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010:465898.
10. Kariuki S.N., Niewold T.B. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res J Lab Clin Med 2010, 155:109-117.
11. Ohl K., Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011, 2011:432595.
12. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
13. Aeberli D., Leech M., Morand E.F. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxf Eng) 2006, 45:937-943.
14. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93:7849-7854.
15. Denkinger C.M., Metz C., Fingerle-Rowson G., Denkinger M.D., Forsthuber T. Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2004, 52:389-400.
16. Postal M., Appenzeller S. The role of Tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011, 56:537-543.
17. Yende S., Angus D.C., Kong L., Kellum J.A., Weissfeld L., Ferrell R., et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J 2009, 23:2403-2411.
18. Radstake T.R.D.J., Sweep F.C.G.J., Welsing P., Franke B., Vermeulen S.H.H.M., Geurts-Moespot A., et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005, 52:3020-3029.
19. Renner P., Roger T., Bochud P.-Y., Sprong T., Sweep F.C.G.J., Bochud M., et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J 2012, 26:907-916.
20. Donn R., Alourfi Z., De Benedetti F., Meazza C., Zeggini E., Lunt M., et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46:2402-2409.
21. Donn R., Alourfi Z., Zeggini E., Lamb R., Jury F., Lunt M., et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004, 50:1604-1610.
22. Llamas-Covarrubias M.A., Valle Y., Bucala R., Navarro-Hernández R.E., Palafox-Sánchez C.A., Padilla-Gutiérrez J.R., et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine 2013, 61:759-765.
23. Zhong X., Leng L., Beitin A., Chen R., McDonald C., Hsiao B., et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res 2005, 33:e121.
24. Oliver J., Márquez A., Gómez-Garcia M., Martinez A., Mendoza J.L., Vilchez J.R., et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut 2007, 56:150-151.
25. Bossini-Castillo L., Simeon C.P., Beretta L., Vonk M.C., Callejas-Rubio J.L., Espinosa G., et al. Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology (Oxf Eng) 2011, 50:1976-1981.
26. Núñez C., Rueda B., Martínez A., López-Nevot M.A., Fernández-Arquero M., de la Concha E.G., et al. Involvement of macrophage migration inhibitory factor gene in celiac disease susceptibility. Genes Immun 2007, 8:168-170.
27. Sánchez E., Gómez L.M., Lopez-Nevot M.A., González-Gay M.A., Sabio J.M., Ortego-Centeno N., et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 2006, 7:433-436.
28. Sreih A., Ezzeddine R., Leng L., LaChance A., Yu G., Mizue Y., et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 2011, 63:3942-3951.
29. Donn R.P., Plant D., Jury F., Richards H.L., Worthington J., Ray D.W., et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 2004, 123:484-487.
30. Baugh J.A., Chitnis S., Donnelly S.C., Monteiro J., Lin X., Plant B.J., et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002, 3:170-176.
31. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
32. Guzmán J., Cardiel M.H., Arce-Salinas A., Sánchez-Guerrero J., Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992, 19:1551-1558.
33. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.
34. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
35. Makhija R., Kingsnorth A., Demaine A. Gene polymorphisms of the macrophage migration inhibitory factor and acute pancreatitis. JOP 2007, 8:289-295.
36. Sullivan K.M., Dean A., Soe M.M. OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Rep 2009, 124:471-474.
37. Calandra T., Bernhagen J., Mitchell R.A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
38. Rangel-Villalobos H., Muñoz-Valle J.F., González-Martín A., Gorostiza A., Magaña M.T., Páez-Riberos L.A. Genetic admixture, relatedness, and structure patterns among Mexican populations revealed by the Y-chromosome. Am J Phys Anthropol 2008, 135:448-461.
39. Bucala R. MIF, MIF Alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol 2012, 33:72-78.
40. Wu S.-P., Leng L., Feng Z., Liu N., Zhao H., McDonald C., et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006, 54:3661-3669.
41. Llamas-Covarrubias M.A., Valle Y., Navarro-Hernández R.E., Guzmán-Guzmán I.P., Ramírez-Dueñas M.G., Rangel-Villalobos H., et al. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int 2012, 32:2307-2311.
42. Foote A., Briganti E.M., Kipen Y., Santos L., Leech M., Morand E.F. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004, 31:268-273.
43. Donn R.P., Ray D.W. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004, 182:1-9.
44. Chen Y.C., Zhang X.W., Niu X.H., Xin D.Q., Zhao W.P., Na Y.Q., et al. Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer. Oncogene 2010, 29:3067-3078.
45. Leech M., Metz C., Santos L., Peng T., Holdsworth S.R., Bucala R., et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998, 41:910-917.
46. Santos L., Hall P., Metz C., Bucala R., Morand E.F. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001, 123:309-314.
47. Onodera S., Ohshima S., Tohyama H., Yasuda K., Nishihira J., Iwakura Y., et al. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 2007, 56:521-530.
48. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.